Natera (NASDAQ:NTRA) Insider Sells $305,900.28 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,204 shares of Natera stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28. Following the transaction, the insider directly owned 132,429 shares in the company, valued at approximately $33,646,236.03. This trade represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45.

Natera Trading Down 0.7%

Shares of NASDAQ NTRA opened at $267.76 on Friday. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $288.04. The company has a market cap of $38.35 billion, a P/E ratio of -164.27 and a beta of 1.51. The stock has a fifty day moving average price of $246.77 and a 200 day moving average price of $222.22.

Institutional Trading of Natera

Several large investors have recently modified their holdings of the business. Horizon Investments LLC increased its position in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the last quarter. Savvy Advisors Inc. grew its stake in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares in the last quarter. Parallel Advisors LLC grew its stake in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares in the last quarter. Finally, First Horizon Corp increased its holdings in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent research reports. William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Canaccord Genuity Group boosted their price target on Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. The Goldman Sachs Group initiated coverage on Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target for the company. Barclays lowered their price objective on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Finally, Sanford C. Bernstein started coverage on shares of Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.